The timing of betamethasone (BMZ) administration in pregnant women does not seem to differentially affect the suppression of the hypothalamic-pituitary-adrenal (HPA) axis and, in turn, has no apparent effect on neonatal outcomes, according to a study presented at recently concluded 40th Annual Pregnancy Meeting of the Society for Maternal Foetal Medicine (SMFM 2020).
Pregnant women may do well to exercise at an adequate amount, as it lowers the likelihood of adverse obstetric outcomes independent of blood pressure, according to a study presented at the Society for Maternal-Fetal Medicine (SMFM) 40th Annual Pregnancy Meeting.
The use of povidone iodine (PI) is more effective than chlorhexidine gluconate (CHG) at reducing vaginal bacterial colony counts in pregnancy and appears to be a superior vaginal antiseptic for decreasing postpartum infections, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Medicine (SMFM 2020).
Being of type O blood may increase the risk of postpartum haemorrhage (PPH) during caesarean delivery, according to a new study presented at the recently concluded 40th Annual Pregnancy Meeting of the Society for Maternal Foetal Medicine (SMFM 2020).
A vegan diet among pregnant women appears to have no impact on the umbilical-cord levels of vitamin B12, folate, ferritin and haemoglobin, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Meeting (SMFM 2020).
In pregnant women with prediabetes or pregestational type 2 diabetes (T2D), metformin also yields protective effects on the risk of pre-eclampsia, as shown in two studies presented at the Society for Maternal-Fetal Medicine (SMFM) 40th Annual Pregnancy Meeting.
Pregnant women with urinary tract infections (UTIs) caused by multidrug-resistant (MDR) bacteria may be at increased risk of developing pyelonephritis, according to a single-centre, retrospective study presented at SMFM 2020.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.